Atezolizumab in addition to paclitaxel and carboplatin is in clinical development for recurrent or primary advanced endometrial cancer (EC). EC (uterine cancer) is cancer of the lining of the womb. Recurrent cancer is cancer that has come back after treatment. Advanced cancer is cancer that cannot normally be cured or controlled. EC is characterised by abnormal vaginal bleeding (after the menopause, between periods) and can also cause symptoms such as pain during sex and lower abdominal (tummy) pain. Typically, advanced EC is treated by using a combination of surgery, radiotherapy and/or chemotherapy. Prognosis of advanced/recurrent EC is poor and treatment options are limited, and there is a need for additional targeted treatment options to improve outcomes for this patient population.
Atezolizumab with paclitaxel and carboplatin for previously untreated advanced endometrial cancer
Atezolizumab in addition to paclitaxel and carboplatin is in clinical development for recurrent or primary advanced endometrial cancer (EC).
Interventions: Atezolizumab (Tecentriq; MPDL3280A) , Carboplatin (Paraplatin) , Paclitaxel (Taxol; paclitaxel albumin)
Indications: Endometrial cancer
Therapeutic Areas: Female Reproductive Cancer